Mometasone furoate dry powder inhaler for the treatment of asthma-Reference-Cited by-同舟云学术

Mometasone furoate dry powder inhaler for the treatment of asthma

Published:2012-12-15 Issue:4 Volume:9 Page:79-87
ISSN:2686-682X
Container-title:Russian Journal of Allergy
language:
Short-container-title:Russian Journal of Allergy

Author:

Emelyanov A V,Goryachkina L A

Abstract

The review is focused on inhaled mometasone furoate (Asmanex Twisthaler), a new medication for the treatment of asthma in adults and childred (12 years and older). Mometasone furoate (MF) has high antiinflammatory activity and low systemic bioavalability. MF has an excellent safety and efficacy profile in approved doses 200—800 mcg/daily od (in the evening) or bid (in the morning and in the evening). For patients with persistent asthma required treatment with an inhaled corticosteroid, MF is an excellent therapeutic choice.

Publisher

Farmarus Print Media

Reference35 articles.

1. Global Initiative for Аsthma. NHLB/WHO Workshop Report. National Heart Lung Blood Institute, Publication number 02-3659, revised 2006. Пер. с англ. под ред. А.Г. Чучалина. М., «Атмосфера». 2007, 103 с.

2. Sharpe M., Jarvis B. Inhaled mometasone furoate. A review of its use in adults and adolescents with persistent asthma. Drugs. 2001, v. 61, p. 1325-1350.

3. Chapman R.W., Sehring S.L., Gallisi C.G. et al. Anti-inflammatory activity of inhaled mometasone furoate in allergic mice. Arzneimittel Forshung. 1998, v. 48, p. 384-391.

4. Barnes P. Optimizing the anti-inflammatory effects of corticosteroids. Eur. Respir. Rev. 2001, v. 11, p. 15-22.

5. Pickering H., Pitcairn G.R., Hirst P.H. et al. Regional lung deposition of technetium 99m-labeled formulation of mometasone furoate administered by hydrofluoralkane 227 metered-dose inhaler. Clin. Ther. 2000, v. 22, p. 1483-1493.